2024
Disordered but effective: short linear motifs as gene therapy targets for hyperexcitability disorders
Dib-Hajj S, Waxman S. Disordered but effective: short linear motifs as gene therapy targets for hyperexcitability disorders. Journal Of Clinical Investigation 2024, 134: e182198. PMID: 38949022, PMCID: PMC11213459, DOI: 10.1172/jci182198.Peer-Reviewed Original ResearchConceptsTetrodotoxin-sensitiveHyperexcitability disordersSensory neuronsExcitability of sensory neuronsGene therapy modalitiesPeripheral sensory neuronsVoltage-gated sodiumMinimal side effectsGene therapyInduce analgesiaTherapy modalitiesSide effectsTherapeutic strategiesNav channelsAttenuating excitationIn vivoHyperexcitabilityAnalgesiaNeuronsDisordersPainTherapyGenesBiodistributionRats
2023
Gene therapy for chronic pain: emerging opportunities in target-rich peripheral nociceptors
Ovsepian S, Waxman S. Gene therapy for chronic pain: emerging opportunities in target-rich peripheral nociceptors. Nature Reviews Neuroscience 2023, 24: 252-265. PMID: 36658346, DOI: 10.1038/s41583-022-00673-7.Peer-Reviewed Original Research
2014
Dysfunction and recovery in demyelinated and dysmyelinated axons
Waxman S. Dysfunction and recovery in demyelinated and dysmyelinated axons. 2014, 457-471. DOI: 10.1017/cbo9780511995583.034.Peer-Reviewed Original ResearchNervous systemNeural repairNormal central nervous systemSpinal cord damageRecovery of functionCentral nervous systemNeuron replacementCerebral palsyCord damageAxonal regenerationNeuronal deathAxon regenerationNeurological rehabilitationBrain disordersCell therapyRehabilitation professionalsRepairRehabilitationBasic scienceStem cell biologyPalsyDysfunctionPathophysiologyInjuryTherapy
2012
Understanding chronic inflammatory and neuropathic pain
Hughes J, Chessell I, Malamut R, Perkins M, Bačkonja M, Baron R, Farrar J, Field M, Gereau R, Gilron I, McMahon S, Porreca F, Rappaport B, Rice F, Richman L, Segerdahl M, Seminowicz D, Watkins L, Waxman S, Wiech K, Woolf C. Understanding chronic inflammatory and neuropathic pain. Annals Of The New York Academy Of Sciences 2012, 1255: 30-44. PMID: 22564068, DOI: 10.1111/j.1749-6632.2012.06561.x.Peer-Reviewed Original Research
2010
Sodium channel expression and function in multiple sclerosis
Bangalore L, Black J, Carrithers M, Waxman S. Sodium channel expression and function in multiple sclerosis. 2010, 29-43. DOI: 10.1017/cbo9780511781698.005.Peer-Reviewed Original ResearchMultiple sclerosisRecovery of functionSodium channel expressionHealth care advisorsMechanisms of recoveryNeurorehabilitation programChannel expressionSpecific syndromesTherapeutic interventionsCare advisorsClinical rehabilitationEfficient therapySclerosisDisease mechanismsPatientsCliniciansNeurorehabilitationInterventionBasic scienceSocial participationPathophysiologySyndromeTherapyNeuroplasticity
2005
Characterizing the Mechanisms of Progression in Multiple Sclerosis: Evidence and New Hypotheses for Future Directions
Frohman E, Filippi M, Stuve O, Waxman S, Corboy J, Phillips J, Lucchinetti C, Wilken J, Karandikar N, Hemmer B, Monson N, De Keyser J, Hartung H, Steinman L, Oksenberg J, Cree B, Hauser S, Racke M. Characterizing the Mechanisms of Progression in Multiple Sclerosis: Evidence and New Hypotheses for Future Directions. JAMA Neurology 2005, 62: 1345-1356. PMID: 16157741, DOI: 10.1001/archneur.62.9.1345.Peer-Reviewed Original ResearchConceptsMultiple sclerosisProgression of MSCause of progressionMechanisms of progressionMS exacerbationDisease courseInflammatory cascadeClinical manifestationsTherapeutic strategiesDisease processTreatment interventionsEvidence-based observationsEmergence of disabilityProgressionDiseasePotential mechanismsTreatment effectsSclerosisProgressive stagesNovel research initiativesExacerbationTherapyIllnessMajor advancementsExpert perspectives